# Pancreatic Neoplasms trials: 472 new since Nov 2024

Updated November 9, 2026.

472 clinical studies in Pancreatic Neoplasms were first posted on ClinicalTrials.gov from November 13, 2024 to November 9, 2026; 122 have an industry sponsor and 390 are recruiting or about to. The newest, NCT07925125, was posted on November 9, 2026: Artificial Intelligence-Assisted 4D Dynamic Long-Axial PET Imaging for the Detection of Early Pancreatic... (Ruijin Hospital).

## The full list

New Pancreatic Neoplasms clinical trials: 472 rows for $23.60, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 22 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/pancreatic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 472
- Industry sponsored: 122
- Recruiting or not yet: 390
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 472, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07925125 | Artificial Intelligence-Assisted 4D Dynamic Long-Axial PET Imaging for the Detection of Early Pancreatic Cancer Lesions | Ruijin Hospital | Observational | Recruiting | Pancreas Carcinoma, PDAC - Pancreatic Ductal Adenocarcinoma | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925125) |
| November 9, 2026 | NCT07924540 | Endoscopic Ultrasound Shear Wave Elastography in Solid Pancreatic Lesions | Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor | Not applicable | Completed | Pancreatic Cancer, Solid Pancreatic Mass Lesions, Pancreatic Adenocarcinoma | 62 | Romania | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924540) |
| November 9, 2026 | NCT07924189 | Association of Psychological Distress With Clinical Outcomes in Patients With Digestive System Cancers | Xuanwu Hospital, Beijing | Observational | Active not recruiting | Psychological Distress, Pancreatic Cancer, Colorectal Cancer, Gastric Cancer | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924189) |
| November 2, 2026 | NCT07911267 | Development and Utilization of an Integrated Clinical Genomic Database | Samsung Medical Center | Observational | Recruiting | Gastric Cancer, Colorectal Cancer, Lung Cancer (NSCLC), Liver Cancer, Pancreatic Cancer | 118,750 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911267) |
| November 2, 2026 | NCT07910383 | The Use of Contrast Enhanced Ultrasound (CEUS) In Post-Surgical Pancreatic Cancer Patients to Evaluate Local Disease Recurrence | Thomas Jefferson University | Not applicable | Recruiting | Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Local Disease | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910383) |
| November 2, 2026 | NCT07909356 | A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha... | Medicovestor, Inc | Phase 1 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer, Metastatic Pancreatic Cancer, Metastatic Solid... | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909356) |
| October 30, 2026 | NCT07906691 | A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Pancreatic Cancer | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906691) |
| October 29, 2026 | NCT07905131 | A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer | Daniel Nussbaum, M.D. | Phase 1/2 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC) | 18 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905131) |
| October 29, 2026 | NCT07903415 | A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. | Pfizer | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma... | 280 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903415) |
| October 27, 2026 | NCT07898813 | Daraxonrasib in Resectable PDAC | Dana-Farber Cancer Institute | Phase 1 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898813) |
| October 26, 2026 | NCT07895498 | A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Pancreatic Cancer, Skin Toxicities | 122 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895498) |
| October 23, 2026 | NCT07892573 | Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of... | Ningbo Medical Center Lihuili Hospital | Not applicable | Recruiting | Pancreatic Cancer | 27 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892573) |
| October 15, 2026 | NCT07875920 | Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation | Neowise Biotechnology | Phase 1 | Not yet recruiting | Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Adenocarcinoma, Lung Adenocarcinoma, KRAS... | 66 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875920) |
| October 15, 2026 | NCT07875582 | Diagnostic Utility of Protein Biomarkers in Pancreatic Ductal Adenocarcinoma | Grigore T. Popa University of Medicine and Pharmacy | Observational | Recruiting | Pancreatic Cancer, Chronic Pancreatitis, Intraductal Papillary Mucinous Neoplasm, Mucinous Cystic Neoplasm | 100 | Romania | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875582) |
| October 14, 2026 | NCT07873606 | Histotripsy x Pancreatic Cancer | The University of Hong Kong | Not applicable | Recruiting | Pancreatic Tumours | 20 | Hong Kong | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873606) |
| October 13, 2026 | NCT07871461 | Utilizing Standard of Care Induction Chemotherapy Followed by MR-LINAC Radiotherapy and Surgical Exploration to Improve Resectability Rates... | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 2 | Not yet recruiting | Pancreatic Cancer | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871461) |
| October 13, 2026 | NCT07871045 | Vascular Resection in Robotic Pancreaticoduodenectomy for Pancreatic Cancer | Taipei Veterans General Hospital, Taiwan | Observational | Completed | Vascular Resection, Pancreatic Cancer, Robotic Pancreaticoduodenectomy | 239 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871045) |
| October 8, 2026 | NCT07864571 | Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic Cancer | Jun Gong, MD | Phase 2 | Not yet recruiting | Pancreatic Cancer | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864571) |
| September 29, 2026 | NCT07845617 | Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma | AdventHealth | Observational | Recruiting | Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma, Duodenal Cancer, Duodenal Adenocarcinoma, Ampullary... | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845617) |
| September 25, 2026 | NCT07843147 | Studies of Blood Glucose and the Microbiome in Tumors and Cysts of the Pancreas | Umeå University | Observational | Not yet recruiting | Pancreatic Neoplasms, Pancreatic Cysts, Hyperglycemia, Prediabetes | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843147) |
| September 24, 2026 | NCT07839676 | A Prospective Study of Concurrent Hyperthermia, Chemotherapy and Radiotherapy in Borderline and Locally Advanced Pancreatic Cancer (PANHEAT) | Fernando Pessoa Canarias University | Not applicable | Not yet recruiting | Borderline and Locally Advanced Pancreatic Cancer | 60 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839676) |
| September 22, 2026 | NCT07833241 | Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Borderline Resectable Pancreatic Cancer, High-Risk Resectable Pancreatic Cancer | 56 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833241) |
| September 21, 2026 | NCT07831694 | Postoperative Outcomes After Partial Duodenopancreatectomy Versus Total Pancreatectomy | Cantonal Hospital of St. Gallen | Observational | Completed | Pancreas Neoplasm | 3,602 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831694) |
| September 18, 2026 | NCT07828756 | Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Pancreatic Cancer | 147 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828756) |
| September 18, 2026 | NCT07828236 | Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Ductal Adenocarcinoma | Loki Therapeutics, Inc. | Phase 1 | Recruiting | Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreatic Cancer, Advanced Pancreatic Adenocarcinoma | 18 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828236) |
| September 18, 2026 | NCT07827911 | Predicting Pancreatic Fistula After Pancreatic Surgery Using Preoperative Immunity | Institut Paoli-Calmettes | Observational | Not yet recruiting | Pancreatic Cancer | 310 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827911) |
| September 17, 2026 | NCT07826780 | The STRONG Nutrition Support Study for People With Pancreatic Cancer | UNC Lineberger Comprehensive Cancer Center | Not applicable | Not yet recruiting | Pancreas Cancer, Metastatic, Pancreas Carcinoma | 80 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07826780) |
| September 17, 2026 | NCT07825870 | Outcomes of Fluoroscopy-Guided Transdiscal Splanchnic Nerve Neurolysis for Upper Abdominal Cancer Pain. | Sahiwal medical college sahiwal | Not applicable | Not yet recruiting | Upper Abdominal Cancer Pain, Pancreatic Cancer, Gastric Cancer, Hepatobiliary Cancer | 40 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825870) |
| September 17, 2026 | NCT07825753 | Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer | Fudan University | Phase 2 | Not yet recruiting | Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC) | 225 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825753) |
| September 17, 2026 | NCT07824960 | Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma | University of Virginia | Phase 1/2 | Not yet recruiting | Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Carcinoma, Locally Advanced... | 31 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824960) |
| September 17, 2026 | NCT07824583 | A Study Evaluating a New Radiation Treatment Workflow (NGDS) | Varian, a Siemens Healthineers Company | Not applicable | Recruiting | Lung Cancer (Diagnosis), Liver Cancer, Adult, Pancreatic Cancer, Thoracic Cancers, Abdominal Cancer | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824583) |
| September 16, 2026 | NCT07823049 | Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy | Evopoint Biosciences Inc. | Phase 3 | Recruiting | Pancreatic Cancer | 226 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823049) |
| September 16, 2026 | NCT07822399 | A Study of MGC030 in Participants With Advanced Solid Tumors | MacroGenics | Phase 1 | Recruiting | Urothelial Cancer, GastroEsophageal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pancreatic Cancer | 314 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822399) |
| September 16, 2026 | NCT07821775 | Robotic vs Laparoscopic and Open Surgery for Abdominopelvic Cancers | Asan Medical Center | Observational | Completed | Pancreatic Neoplasms, Stomach Neoplasms, Rectal Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Kidney... | 32,949 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821775) |
| September 16, 2026 | NCT07821554 | Personalised Nutritional Care in Older Patients With Pancreatic Ductal Adenocarcinoma | Inna Chen, MD | Not applicable | Not yet recruiting | Pancreatic Cancer | 250 | Denmark, Italy, Norway, Romania, Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821554) |
| September 14, 2026 | NCT07817602 | Real-world Evaluation of Different Endoscopic Biliary Drainage Techniques in Patients With Jaundice of Biliopancreatic Malignant Origin | Centre Hospitalier Universitaire de Nīmes | Observational | Not yet recruiting | Biliary Drainage, Endoscopic Ultrasound-Guided Drainage, Pancreatic Cancer | 300 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817602) |
| September 14, 2026 | NCT07817147 | CREO - Microwave Ablation Feasibility Study | Banner Health | Not applicable | Recruiting | Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic), Pancreatic Cancer Non-resectable, Pancreatic Cancer... | 75 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817147) |
| September 11, 2026 | NCT07814872 | A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | Harvard Medical School (HMS and HSDM) | Observational | Not yet recruiting | Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Pancreatic... | 30,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814872) |
| September 11, 2026 | NCT07814859 | Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic... | The First Affiliated Hospital of Zhengzhou University | Phase 2 | Not yet recruiting | Pancreatic Cancer | 88 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814859) |
| September 10, 2026 | NCT07814326 | Feasibility of the Loop Brush EUS-FNA for Characterization of Pancreatic Cysts: Pilot Clinical Investigation | Urban Arnelo | Not applicable | Not yet recruiting | Pancreatic Cancer | 8 | Sweden | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814326) |
| September 10, 2026 | NCT07814066 | A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With... | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Pancreatic Cancer | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814066) |
| September 9, 2026 | NCT07809841 | Real-Time AI During Pancreatoscopy for Detection of Pancreatic Neoplasia | Instituto Ecuatoriano de Enfermedades Digestivas | Observational | Not yet recruiting | Intraductal Papillary Mucinous Neoplasm of Pancreas, Pancreatic Neoplasms | 60 | Ecuador | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809841) |
| September 9, 2026 | NCT07808671 | A Decision Support Tool for Pancreatic Cancer Screening -Aim 2 | UNC Lineberger Comprehensive Cancer Center | Not applicable | Not yet recruiting | Pancreas Cancer | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808671) |
| September 8, 2026 | NCT07808164 | ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort | Tam Anh Research Institute | Observational | Recruiting | HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Gastric Carcinoma, Breast Cancer, Lung Cancer, Endometrial... | 162 | Vietnam | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808164) |
| September 8, 2026 | NCT07806058 | An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors | Jiangsu HengRui Medicine Co., Ltd. | Phase 1/2 | Recruiting | Pancreatic Cancer | 140 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806058) |
| September 8, 2026 | NCT07805954 | Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic... | Revolution Medicines, Inc. | Phase 3 | Recruiting | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal... | 400 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805954) |
| September 4, 2026 | NCT07805681 | Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test for Early-Stage Pancreatic Ductal Adenocarcinoma | Immunovia, Inc. | Observational | Not yet recruiting | PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage I, Pancreatic Cancer Stage II, Cancer Diagnosis | 400 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805681) |
| September 4, 2026 | NCT07803783 | A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure... | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 3 | Not yet recruiting | Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | 320 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803783) |
| September 4, 2026 | NCT07803770 | EUS-Based Artificial Intelligence to Predict Outcomes in Pancreatic Cancer | IRCCS San Raffaele | Observational | Not yet recruiting | Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma (PDAC), Artificial Intelligence (AI), Endoscopic Ultrasound... | 700 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803770) |
| September 3, 2026 | NCT07802418 | Molecularly Tailored Therapy in Advanced Pancreatic Cancer | Herlev Hospital | Phase 2 | Not yet recruiting | Pancreatic Cancer | 1,200 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802418) |
| September 3, 2026 | NCT07802184 | GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC | West China Hospital | Phase 1/2 | Recruiting | Metastatic Pancreatic Cancer | 45 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802184) |
| September 2, 2026 | NCT07799298 | Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Not applicable | Not yet recruiting | Pancreatic Cancer, Pancreatectomy, Adenocarcinoma Pancreas | 360 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07799298) |
| September 1, 2026 | NCT07796997 | GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy | University of Illinois Chicago | Phase 1 | Not yet recruiting | Pancreatic Cancer, Pancreatic Adenocarcinoma, Duodenal Cancer, Distal Cholangiocarcinoma | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796997) |
| September 1, 2026 | NCT07796906 | Five-Element Music Therapy for Psychological Distress in Pancreatic Cancer Chemotherapy | Tianjin Medical University Cancer Institute and Hospital | Not applicable | Not yet recruiting | Pancreatic Neoplasms, Pancreatic Cancer, Anxiety, Depression and/or Anxiety Symptoms, Psychological Distress | 320 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796906) |
| September 1, 2026 | NCT07796594 | Integration of Whole-Genome Sequencing PrOfiles and ImmuNe StATus in Cancer | Amsterdam UMC, location VUmc | Not applicable | Active not recruiting | Melanoma, Pancreas Cancer | 180 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796594) |
| August 31, 2026 | NCT07794969 | Pancreatic Cancer Lifestyle Evolution And Resistance | IRCCS San Raffaele | Observational | Not yet recruiting | Pancreatic Cancer | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794969) |
| August 28, 2026 | NCT07791550 | Baduanjin for Quality of Life in Pancreatic Cancer Chemotherapy | Tianjin Medical University Cancer Institute and Hospital | Not applicable | Not yet recruiting | Pancreatic Neoplasms, Pancreatic Cancer, Drug-Related Side Effects and Adverse Reactions (MeSH Term) | 96 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791550) |
| August 26, 2026 | NCT07787156 | Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial | Brigham and Women's Hospital | Not applicable | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Family History of Pancreas Cancer, Genetic Testing, Multi-cancer Early... | 80 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07787156) |
| August 25, 2026 | NCT07784374 | A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable... | Genfleet Therapeutics (Shanghai) Inc. | Phase 2 | Recruiting | Pancreatic Cancer | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784374) |
| August 24, 2026 | NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | Lumina Pharmaceuticals Inc | Early phase 1 | Not yet recruiting | Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC)... | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781852) |
| August 20, 2026 | NCT07776353 | Understanding New Cachexia Subtypes Through Observational Epidemiological Research | Kaiser Permanente | Observational | Recruiting | Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV... | 800 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776353) |
| August 19, 2026 | NCT07773363 | Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer | Tang-Du Hospital | Phase 2 | Not yet recruiting | Pancreatic Cancer | 37 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07773363) |
| August 19, 2026 | NCT07772258 | Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for Pancreatic Cancer | Manchester University NHS Foundation Trust | Not applicable | Not yet recruiting | Pancreatic Cancer, Pancreatic Neoplasms, Periampullary Carcinoma, Pancreatic Surgery, Perioperative Care | 120 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07772258) |
| August 14, 2026 | NCT07765836 | Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC | Massachusetts General Hospital | Phase 2 | Not yet recruiting | Pancreatic Cancer Metastatic | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765836) |
| August 13, 2026 | NCT07763561 | EUS-DFI in Solid Pancreatic Lesions | Julio Iglesias García | Observational | Not yet recruiting | Pancreatic Neoplasms, Pancreatic Solid Lesions | 48 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763561) |
| August 13, 2026 | NCT07763301 | YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies | West China Hospital | Phase 1 | Recruiting | Liver Cancer, Pancreatic Cancer, Biliary Tract Cancer (BTC) | 9 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763301) |
| August 13, 2026 | NCT07762950 | Blood Biomarkers and Gut Microbiota for Pancreatic Cancer Risk in Chronic Pancreatitis | Changhai Hospital | Observational | Not yet recruiting | Chronic Pancreatitis, Pancreatic Cancer | 800 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762950) |
| August 12, 2026 | NCT07760012 | 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors | Peking University Third Hospital | Not applicable | Recruiting | Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer, Pancreatic Cancer, Ovarian Cancer... | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760012) |
| August 10, 2026 | NCT07756281 | First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer | ParVation Therapeutics, Inc. | Phase 1 | Recruiting | Pancreatic Cancer, Pancreatic Acinar Carcinoma | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756281) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| August 4, 2026 | NCT07745790 | Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With... | Ruijin Hospital | Phase 2 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma, Liver Neoplasms, Lung Neoplasms | 20 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745790) |
| July 30, 2026 | NCT07737171 | Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions | The University of Texas Health Science Center, Houston | Observational | Recruiting | Pancreatic Cancer | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07737171) |
| July 30, 2026 | NCT07736612 | A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer | Zhejiang University | Phase 1/2 | Not yet recruiting | Pancreatic Cancer, RAS Mutations or Amplifications | 80 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736612) |
| July 29, 2026 | NCT07733674 | Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma... | Radiomedix, Inc. | Phase 1 | Recruiting | Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC) | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733674) |
| July 29, 2026 | NCT07733427 | Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic Cancer | Clinique Bizet | Not applicable | Not yet recruiting | Pancreatic Cancer Pain, Intrathecal Analgesic, Intrathecal Administration of the Drug, Pancreatic Carcinoma | 40 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733427) |
| July 29, 2026 | NCT07732686 | Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry | University of Oklahoma | Observational | Not yet recruiting | Pancreas Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Cancer, Colon... | 2,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732686) |
| July 23, 2026 | NCT07723781 | Structured Case-Finding for Pancreatic Ductal Adenocarcinoma in Swiss Primary Care: A Feasibility Study | Saskia Hendrich | Observational | Not yet recruiting | Pancreatic Adenocarcinoma (Ductal Adenocarcinoma), Early Detection of Cancer | 50 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723781) |
| July 20, 2026 | NCT07714538 | Breath Research Narrow Validation for Gastrointestinal Cancer Detection | Imperial College London | Observational | Recruiting | Oesophageal Squamous Cell Carcinoma, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Ductal... | 1,000 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714538) |
| July 20, 2026 | NCT07713823 | Study on the Construction and Application of a Large Model Corpus for Pancreatic Cancer Based on Real Clinical Cases | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Observational | Not yet recruiting | Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable | 3,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713823) |
| July 16, 2026 | NCT07707674 | Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer | Evopoint Biosciences Inc. | Phase 1 | Not yet recruiting | Metastatic Pancreatic Cancer | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07707674) |
| July 16, 2026 | NCT07707531 | A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and... | Huashan Hospital | Early phase 1 | Recruiting | Gastric Cancer, Pancreatic Cancer | 10 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07707531) |
| July 15, 2026 | NCT07704021 | Safety and Efficacy of EUS-guided Gallbladder Drainage Under Endoscopist-directed Conscious Sedation | Azienda Unita Sanitaria Locale di Piacenza | Observational | Completed | Cholecystitis, Acute, Pancreas Cancer, Duct Cell Adenocarcinoma, Cholangiocarcinoma | 48 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704021) |
| July 14, 2026 | NCT07703813 | Energy Expenditure and Nutrition After Pancreatic Surgery | Evangelismos Hospital | Observational | Recruiting | Whipple Procedures, Pancreatic Cancer, Pancreaticoduodenectomy, Pancreatic Neoplasms | 150 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703813) |
| July 14, 2026 | NCT07701486 | A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer | Theriva Biologics SL | Phase 1/2 | Recruiting | Pancreas Cancer, Metastatic, Pancreas Cancer, Stage IV, Ductal Adenocarcinoma of the Pancreas | 6 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07701486) |
| July 14, 2026 | NCT07700992 | A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring | Università Vita-Salute San Raffaele | Observational | Recruiting | Familial Pancreatic Cancer, Familial Pancreatic Carcinoma, Hereditary Pancreatic Cancer, Hereditary Pancreatitis... | 600 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07700992) |
| July 13, 2026 | NCT07697170 | Frequency of Care for Peripherally Inserted Central Vascular Access In the Prevention of Marsi | Institut Català d'Oncologia | Not applicable | Enrolling by invitation | Colon Cancer, Cancer Pancreas | 150 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697170) |
| July 9, 2026 | NCT07691593 | Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer | Changhai Hospital | Phase 2 | Not yet recruiting | Pancreatic Cancer | 60 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691593) |
| July 8, 2026 | NCT07689955 | A Phase-II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer | Royal Marsden NHS Foundation Trust | Phase 2 | Not yet recruiting | Pancreatic Cancer | 52 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689955) |
| July 8, 2026 | NCT07689539 | Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Pancreatic Cancer | 360 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689539) |
| July 6, 2026 | NCT07683221 | SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer | Shandong Cancer Hospital and Institute | Phase 2 | Recruiting | Pancreatic Cancer | 47 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683221) |
| June 26, 2026 | NCT07671937 | INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study | University of Alabama at Birmingham | Not applicable | Recruiting | Breast Cancer, Corpus Uteri Cancer, Ovary Cancer, Pancreas Cancer, Other Female Genital Malignant Neoplasms | 2,748 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671937) |
| June 26, 2026 | NCT07671339 | A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Pancreatic Cancer | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671339) |
| June 26, 2026 | NCT07670871 | Exocrine-Endocrine Pancreatic Crosstalk: Precision Pathways to Reframe Diabetes Pathophysiology | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Not yet recruiting | Type 2 Diabetes Mellitus (T2DM), Chronic Pancreatitis, Prediabetes, Pancreatic Neoplasms | 440 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670871) |
| June 26, 2026 | NCT07670286 | Spatial Multi-omics and Intelligent Early Warning of Pancreatic Cancer Cachexia | Peking Union Medical College Hospital | Observational | Recruiting | Pancreatic Cancer, Cachexia; Cancer; Sarcopenia | 500 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670286) |
| June 25, 2026 | NCT07668024 | Study of Occupational Risk Factors for Biliary and Pancreatic Cancers | Centre Hospitalier Intercommunal Creteil | Observational | Not yet recruiting | Biliary Tract Cancer, Pancreatic Cancer | 210 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668024) |
| June 24, 2026 | NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer | University Health Network, Toronto | Phase 1/2 | Not yet recruiting | Pancreas Ductal Adenocarcinoma, Pancreas Cancer, Metastatic, Pancreatic Adenocarcinoma Metastatic, Adenosquamous... | 67 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07665684) |
| June 22, 2026 | NCT07660627 | Determining Minimal Residual Disease Using ctDNA Deep Sequencing | Masaryk Memorial Cancer Institute | Not applicable | Recruiting | Esophageal Adenocarcinoma, Gastric Cancer, Pancreatic Cancer | 34 | Czechia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660627) |
| June 18, 2026 | NCT07658313 | Digitally Supported Prehabilitation Before Major Visceral Cancer Surgery | Ludwig Boltzmann Institute for Digital Health and Prevention | Not applicable | Not yet recruiting | Gastrointestinal Neoplasms, Pancreatic Neoplasms, Liver Neoplasm, Oesophageal Cancer, Gastrointestinal Cancer... | 30 | Austria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658313) |
| June 18, 2026 | NCT07656571 | Indocyanine Green-Guided Versus Standard Laparoscopic Distal Pancreatectomy for Pancreatic Body and Tail Lesions | Alexandria University | Not applicable | Recruiting | Pancreatic Neoplasms, Pancreatic Cancer | 72 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07656571) |
| June 18, 2026 | NCT07656376 | Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With... | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Phase 2/3 | Not yet recruiting | Pancreatic Cancer, Pancreatic Carcinoma | 465 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07656376) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Minia University | 10 | November 18, 2025 |
| Changhai Hospital | 9 | August 13, 2026 |
| Ruijin Hospital | 7 | November 9, 2026 |
| Shanghai Zhongshan Hospital | 6 | September 22, 2026 |
| Tianjin Medical University Cancer Institute and Hospital | 6 | September 18, 2026 |
| Revolution Medicines, Inc. | 6 | September 8, 2026 |
| Zhejiang University | 6 | July 30, 2026 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 6 | June 26, 2026 |
| Peking Union Medical College Hospital | 6 | June 26, 2026 |
| Fudan University | 5 | September 17, 2026 |
| West China Hospital | 5 | September 3, 2026 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 5 | July 20, 2026 |
| Shandong Cancer Hospital and Institute | 5 | July 6, 2026 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 5 | June 16, 2026 |
| Memorial Sloan Kettering Cancer Center | 4 | October 26, 2026 |
| IRCCS San Raffaele | 4 | September 4, 2026 |
| National Cancer Institute (NCI) | 4 | June 2, 2026 |
| Pfizer | 3 | October 29, 2026 |
| UNC Lineberger Comprehensive Cancer Center | 3 | September 17, 2026 |
| Evopoint Biosciences Inc. | 3 | September 16, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 136 | November 9, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 107 | November 9, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 72 | October 26, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 59 | October 29, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 50 | November 2, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 25 | September 16, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 14 | August 24, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 7 | June 18, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 2 | April 29, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 147 | November 2, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 145 | November 9, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 31 | September 24, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 29 | September 16, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 25 | September 18, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 22 | November 2, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 21 | June 24, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 18 | July 20, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 17 | June 12, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 16 | May 18, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 12 | October 13, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 11 | June 18, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 10 | September 16, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 10 | May 26, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 9 | September 2, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 8 | April 13, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 8 | March 24, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 7 | July 23, 2026 |
| [Austria](https://specstream.ai/data/clinical-trials/country/austria) | 7 | June 18, 2026 |
| [Sweden](https://specstream.ai/data/clinical-trials/country/sweden) | 6 | September 10, 2026 |
| [Puerto Rico](https://specstream.ai/data/clinical-trials/country/puerto-rico) | 6 | June 12, 2026 |
| [Romania](https://specstream.ai/data/clinical-trials/country/romania) | 5 | November 9, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 5 | May 1, 2026 |
| [Hong Kong](https://specstream.ai/data/clinical-trials/country/hong-kong) | 4 | October 14, 2026 |
| [Norway](https://specstream.ai/data/clinical-trials/country/norway) | 4 | September 16, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).